welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
NIH Awards $86 Million to Improve Genome Editing Techniques
Somatic Cell Genome Editing support is aimed at improving therapeutic options for both rare and common diseases.
Making changes to a patients DNA can have powerful implications for the treatment of disease. To tap into this immense potential, NIH recently awarded 21 Somatic Cell Genome Editing grants — totaling approximately $86 million over the next five years, pending available funds — to support research aimed at improving methods to edit the human genome. These grants are the first to be awarded through the Somatic Cell Genome Editing (SCGE) program, which was launched in January 2018 with NIH Common Fund support. As a trans-NIH endeavor, SCGE is managed by staff from multiple NIH Institutes and Centers, with leadership from NCATS.
rareRelated
-
Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and CanadaDuchenne/Becker muscular dystrophy (DBMD...
-
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...
-
Study of Eteplirsen in DMD PatientsThe main objective of this study is to p...
-
Ryan Benton Discusses Stem Cell Therapy for Duchenne Muscular Dystrophyhttps://www.youtube.com/watch?v=K94yWLJf...
-
Tom’s Story – Duchenne muscular dystrophy – Action Medical Researchhttps://www.youtube.com/watch?v=VWL2oGDe...
-
Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential...Catabasis Pharmaceuticals, Inc., a clini...
-
First Duchenne Drug Approved by the FDAhttps://www.youtube.com/watch?v=xQWfXKL1...